Experimental prostate cancer therapy delays disease in ‘landmark’ trial
(CNN) -- An experimental prostate cancer therapy may change the way patients are treated for the second-deadliest cancer in men. In a "landmark" phase III clinical trial, presented at the European Society of Medical Oncology conference in Barcelona on Monday, the drug olaparib was shown to be safe and effective in delaying the progression of disease in men with both metastatic castrate-resistant prostate cancer and mutations in their homologous recombination repair, or HRR, genes.